Latest Conference Articles

Patients with advanced, pretreated ROS1-positive NSCLC treated with zidesamtinib saw an objective response rate of 44%.

People with EGFR+ NSCLC whose disease spread outside the brain after treatment with Tagrisso lived longer when they kept taking Tagrisso along with chemo.

A combination of Iza-bren and Tagrisso showed beneficial results as an initial treatment for advanced/metastatic EGFR-mutated non–small cell lung cancer.

Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.

PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.

Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.

Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.

Early data suggest personalized neoantigen vaccines activate the immune system and sustain tumor control in some patients with kidney cancer.

Personalized cancer vaccines may potentially represent a step forward in guiding the immune system to more precisely target kidney cancer.

An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.

The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.

Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.

Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.

Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.

The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.

Sara Gideon, nurse practitioner, is a compassionate oncology nurse who supports patients with cancer, streamlines care and leads with dedication.

Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.